Not only useful in the third world.

China kept deaths low by turning China into a ghost town last year at the COVID 19 outbreak. Conversely, US deaths were 150 times higher than in China. However, now China could be facing much different statistics with having a vaccine that is only 30%+ effective and because of keeping people off the street to minimize the death count, they did not build up natural immunity amongst the general population of 1.4 billion people.

Depending on what China could potentially be faced with, Resverlogix/Shenzhen Hepalink needs to take advantage of whatever develops with the different COVID 19 variants outbreaks yet to come. All dependant of course with a successful Open-Label Covid 19 trial. Great potential for Apabetalone.

IMO ... Koo